<DOC>
	<DOCNO>NCT01259557</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Meditoxin® treatment Essential blepharospasm .</brief_summary>
	<brief_title>Efficacy Safety Study Meditoxin® Treat Essential Blepharospasm</brief_title>
	<detailed_description />
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Men woman age 18 Subjects diagnose Essential Blepharospasm Subjects voluntarily Signed write informed consent Subjects adhere protocol study requirement Subjects known history allergy consider due Botulinum toxin type A Subjects receive botulinum toxin A type within 3 month Any disease might affect neuromuscular function ( e.g.. Myasthenia Gravis , LambertEaton Syndrome , Amyotrophic Lateral Sclerosis ect . ) Subjects participate clinical trial Pregnant lactate female Subjects Subjects eligible study discretion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>